Fannie Mae, Freddie Mac shares tumble after conservatorship comments
PITTSBURGH -On Thursday, Viatris Inc. (NASDAQ:VTRS) the pharmaceutical company reported fourth quarter earnings and revenue that missed analyst expectations and provided weaker-than-anticipated guidance for 2025.
The stock was down -5.43% in premarket trading following the earnings release.
The company posted adjusted earnings per share of $0.54 for Q4, falling short of the $0.58 consensus estimate. Revenue came in at $3.52 billion, below Wall Street’s projection of $3.62 billion.
For the full year 2024, Viatris reported total revenues of $14.7 billion, adjusted EBITDA of $4.7 billion, and adjusted EPS of $2.65.
Looking ahead, Viatris forecast 2025 revenue between $13.5 billion and $14 billion, below the $14.22 billion analysts were expecting. The company’s adjusted EPS guidance of $2.12 to $2.26 for 2025 also disappointed compared to the $2.59 consensus.
CEO Scott A. Smith said 2024 was "a good year for Viatris with full year operational revenue growth of 2%, excluding divestitures, in line with our guidance." However, the company’s outlook suggests challenges ahead.
Viatris noted its 2025 guidance includes an anticipated negative impact from an FDA warning letter and import alert at its Indore, India facility. The company estimates this will reduce 2025 revenues by approximately $500 million and adjusted EBITDA by about $385 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.